Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
2030 sales: $2.8 billion Aficamten (CK-274) is a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy
It was developed at the University of Arizona by Hruby and Hadley and contains two key modifications from native -MSH: a norleucine substitution at position 4 (replacing methionine) and a D-phenylalanine substitution at position 7 (replacing L-phenylalanine)
If you experience persistent pain during injection, your needle may be too small, you may be injecting too quickly, or the medication may still be cold
Note: This is a significant update as codes in category C7A are CCs
Constipation is managed with adequate fiber, hydration, and if needed, gentle fiber supplements
L.CaparelliE
US$ 29.17
US$ 22.28
US$ 24.53
